RECRUITING

Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

Talk to us

Conditions

Malignant Neoplasm

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research trial studies the use of targeted genomic analysis of blood and tissue samples from patients with cancer. Genomic sequencing is a laboratory method that is used to determine the entire genetic makeup of a specific organism or cell type. Genomic sequencing can be used to find changes in areas of the genome that may be important in the development of cancer. It may also help doctors improve ways to diagnose and treat patients with rare cancers with poor prognosis or lack of effective therapy.

Official Title

Targeted Genomic Analysis of Human Cancers

Quick Facts

Study Start:2013-02
Study Completion:2030-05
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02688517

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:1 Year
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Karnofsky/Lansky performance score \>= 30
  2. * A signed written informed consent
  3. * Evaluation in surgical/medical/radiation oncology/radiology clinic, with a history of biopsy-confirmed diagnosis of cancer of rare histology and/or poor prognosis with standard therapy; priority will be given to rare cancers with poor prognosis and lack of effective standard therapy; study principal investigator (PI) or designee will review and approve each case before enrollment
  4. * Paraffin blocks of the patient's tumor tissue are available and accessible for analysis
  1. * Karnofsky/Lansky performance score \< 30
  2. * Life expectancy \< 3 months

Contacts and Locations

Study Contact

Clinical Trials Office
CONTACT
732-235-2465

Principal Investigator

Shridar Ganesan
PRINCIPAL_INVESTIGATOR
Rutgers Cancer Institute of New Jersey

Study Locations (Sites)

Ocean Medical Center
Brick, New Jersey, 08724
United States
Bayshore Community Hospital
Holmdel, New Jersey, 07733
United States
RWJBarnabas Health - Jersey City Medical Center, Jersey City
Jersey City, New Jersey, 07302
United States
Southern Ocean County Medical Center
Manahawkin, New Jersey, 08050
United States
Morristown Medical Center
Morristown, New Jersey, 07960
United States
Jersey Shore Medical Center
Neptune, New Jersey, 07753
United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
United States
Riverview Medical Center/Booker Cancer Center
Red Bank, New Jersey, 07701
United States
Riverview Medical Center
Red Bank, New Jersey, 07701
United States
Overlook Hospital
Summit, New Jersey, 07902
United States
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53792
United States

Collaborators and Investigators

Sponsor: Rutgers, The State University of New Jersey

  • Shridar Ganesan, PRINCIPAL_INVESTIGATOR, Rutgers Cancer Institute of New Jersey

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2013-02
Study Completion Date2030-05

Study Record Updates

Study Start Date2013-02
Study Completion Date2030-05

Terms related to this study

Additional Relevant MeSH Terms

  • Malignant Neoplasm